Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort
Onc File published (year): 2020
Oncoinvent CEO, Jan A. Alfheim presented the company at the virtual Hadean Ventures Annual Event 2020. The presentation is available here (https://www.youtube.com/watch?v=f_cJUHC4vSg&feature=emb_logo).
Oncoinvent will present the e-poster “Size-controlled 224Ra-labelled calcium carbonate microparticles against peritoneal carcinomatosis” at the virtual 33rd annual European Association of Nuclear Medicine (EANM) Congress. The abstract (no. EP-290) can be downloaded here.
Oncoinvent CEO, Jan A. Alfheim will present the company at the virtual Nordic American Life Science Conference.
Oncoinvent would like to extend an invitation to a presentation of the Q3 2020 results. The presentation will be held virtually at 10:00 on Friday 23. October 2020. We request that participants register with email@example.com for logon details. The quarterly report will be made available on www.oncoinvent.com on the 23. October 2020.
Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that a second phase 1 clinical trial of it’s lead candidate compound Radspherin® has been initiated. The first ovarian cancer patient has been treated with Radspherin® at the Radium Hospital in Oslo under the guidance of clinical investigator Dr. Yun Wang, M.D., Ph.D.
Reference is made to the extraordinary general meeting notice published on 20th of May 2020 regarding a repair issue with gross proceeds of up to NOK 9 million directed towards eligible shareholders and company employees (the “Repair Issue”). The Repair Issue consisted of an offer of minimum 1 and maximum 175,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible shareholders and an offer of minimum 1 and maximum 25,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible employees. The subscription period for the Repair Issue ended on 29th of May 2020 at 16.30 hours (CEST). The subscription price in the Repair Issue was NOK 45 per Offer Share.
Press Release 02.2020:
Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin®.